BMRN Biomarin Pharmaceutical Inc

Price (delayed)

$81.83

Market cap

$14.85B

P/E Ratio

17.37

Dividend/share

N/A

EPS

$4.71

Enterprise value

$15.29B

Sector: Healthcare
Industry: Biotechnology

Highlights

The equity has grown by 32% YoY and by 25% from the previous quarter
The revenue has grown by 16% YoY
Biomarin Pharmaceutical's gross profit has increased by 8% YoY but it has decreased by 5% QoQ
The debt has soared by 72% year-on-year
BMRN's gross margin is down by 7% year-on-year and by 6% since the previous quarter

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
181.53M
Market cap
$14.85B
Enterprise value
$15.29B
Valuations
Price to earnings (P/E)
17.37
Price to book (P/B)
3.66
Price to sales (P/S)
7.96
EV/EBIT
781.08
EV/EBITDA
124.11
EV/Sales
8.21
Earnings
Revenue
$1.86B
EBIT
$19.57M
EBITDA
$123.18M
Free cash flow
$89.18M
Per share
EPS
$4.71
Free cash flow per share
$0.49
Book value per share
$22.35
Revenue per share
$10.28
TBVPS
$30.55
Balance sheet
Total assets
$6.16B
Total liabilities
$2.1B
Debt
$1.45B
Equity
$4.05B
Working capital
$1.88B
Liquidity
Debt to equity
0.36
Current ratio
3.2
Quick ratio
2.24
Net debt/EBITDA
3.51
Margins
EBITDA margin
6.6%
Gross margin
73.5%
Net margin
45.7%
Operating margin
-0.1%
Efficiency
Return on assets
16.3%
Return on equity
25%
Return on invested capital
0.5%
Return on capital employed
0.4%
Return on sales
1.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-1.79%
1 week
-1.73%
1 month
-8.03%
1 year
-10.08%
YTD
-6.68%
QTD
-6.68%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$1.86B
Gross profit
$1.37B
Operating income
-$1.09M
Net income
$852.03M
Gross margin
73.5%
Net margin
45.7%
Biomarin Pharmaceutical's operating margin has plunged by 103% from the previous quarter but it has soared by 99% YoY
The operating income has dropped by 102% since the previous quarter but it has surged by 99% year-on-year
The revenue has grown by 16% YoY
Biomarin Pharmaceutical's gross profit has increased by 8% YoY but it has decreased by 5% QoQ

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
17.37
P/B
3.66
P/S
7.96
EV/EBIT
781.08
EV/EBITDA
124.11
EV/Sales
8.21
The stock's price to book (P/B) is 32% less than its 5-year quarterly average of 5.4 and 27% less than its last 4 quarters average of 5.0
The equity has grown by 32% YoY and by 25% from the previous quarter
BMRN's price to sales (P/S) is 29% less than its 5-year quarterly average of 11.2 and 13% less than its last 4 quarters average of 9.2
The revenue has grown by 16% YoY

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 118% YoY but it has plunged by 77% from the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 117% YoY but it has shrunk by 76% QoQ

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
The total assets is 193% more than the total liabilities
The total assets has grown by 35% YoY and by 16% from the previous quarter
The debt is 64% smaller than the equity
BMRN's debt to equity is up by 33% year-on-year but it is down by 20% since the previous quarter
The equity has grown by 32% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.